February 13, 2020

Seqster Secures Investment from Takeda Pharmaceuticals

““Our funding of Seqster is a cornerstone of our digital health strategy, and further enables us to serve our patient community by advancing the deployment of innovative technology solutions,” stated Bruce Meadows, Head of Investments at Takeda Digital Ventures. “Seqster’s technology is a very unique platform that addresses interoperability on not only a nationwide scale but also globally. Interoperability is one of the biggest barriers to applying precision medicine to clinical trials and patient engagement.”“

Investment solidifies Seqster’s leadership position in making health data as medicine with patient-mediated interoperability technology


SAN DIEGO, February 13, 2020 — Seqster, the award-winning SaaS-based technology platform enabling person-centric health data management, today announced that the company has secured investment from Takeda Pharmaceuticals, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. The funds invested in Seqster will be used to accelerate the adoption of Seqster’s interoperability technology for enhancing clinical trials, patient engagement, and outcomes.

“We are thrilled to have Takeda Pharmaceuticals as a strategic investor sharing our vision and mission of putting patients at the center of all of their health data and making health data into medicine,” stated Ardy Arianpour, Seqster’s CEO and co-founder. “We have created a unique data-sharing environment that retrieves, parses and harmonizes multi-dimensional data sets thereby accelerating the entire drug development process with high fidelity data hosted within a HIPAA-compliant and HiTrust data schema. Seqster provides clinical trial participants a secure platform to consent and share their data with investigators and study personnel in real-time creating a longitudinal health record that facilitates patient clinical trial onboarding, monitoring and post-trial follow-ups.”

The recently released Seqster Version 5.0 creates a seamless and personalized patient experience, delivering improved patient outcomes, generating actionable data, and enhancing value across the patient journey from clinical to commercial. It is supported by a platform designed for patients and their needs, featuring one core patient engagement platform that brings disparate data sets together in a common form.

“Our funding of Seqster is a cornerstone of our digital health strategy, and further enables us to serve our patient community by advancing the deployment of innovative technology solutions,” stated Bruce Meadows, Head of Investments at Takeda Digital Ventures. “Seqster’s technology is a very unique platform that addresses interoperability on not only a nationwide scale but also globally. Interoperability is one of the biggest barriers to applying precision medicine to clinical trials and patient engagement.”

“We couldn’t be more excited to be contributing to empowering patients to access their health data and share it on their own terms,” explained Janine Kopp, Venture Associate at Takeda Digital Ventures.

Contact Us

We’d love to hear from you.